phenprocoumon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
anticoagulants, dicoumarol derivatives 2138 435-97-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phenprocoumon
  • fencumar
  • marcoumar
  • phenprocoumarol
  • phenprocoumarole
  • liquamar
Coumarin derivative that acts as a long acting oral anticoagulant.
  • Molecular weight: 280.32
  • Formula: C18H16O3
  • CLOGP: 4.71
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.53
  • ALOGS: -3.76
  • ROTB: 3
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.43 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.02 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.57 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 126 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 100 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.682 Moderate 0.73
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.73
rat-kpuu-brain Rat brain Kpuu 0.873 % Moderate 0.73

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1957 FDA ORGANON USA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product monitoring error 273.85 26.10 65 7065 4479 90616838
Product prescribing error 258.56 26.10 95 7035 30050 90591267
General physical health deterioration 237.78 26.10 207 6923 354908 90266409
Anaemia 143.99 26.10 157 6973 352645 90268672
Haematoma 133.67 26.10 64 7066 38984 90582333
Acute kidney injury 131.40 26.10 143 6987 320244 90301073
Haematochezia 128.42 26.10 76 7054 70837 90550480
Drug interaction 126.82 26.10 131 6999 276322 90344995
Atrial fibrillation 114.22 26.10 90 7040 133521 90487796
Labelled drug-drug interaction medication error 110.48 26.10 42 7088 14540 90606777
Cardiac failure 102.81 26.10 78 7052 109418 90511899
International normalised ratio increased 102.46 26.10 57 7073 47259 90574058
Fall 76.34 26.10 136 6994 481674 90139643
Therapeutic drug monitoring analysis not performed 74.80 26.10 18 7112 1311 90620006
Bradycardia 72.70 26.10 57 7073 83790 90537527
Pallor 70.79 26.10 40 7090 34125 90587192
Prothrombin time prolonged 69.90 26.10 27 7103 9745 90611572
Drug ineffective 68.93 26.10 13 7117 1384285 89237032
Electrocardiogram abnormal 68.53 26.10 27 7103 10271 90611046
Device stimulation issue 57.86 26.10 9 7121 59 90621258
Dehydration 56.61 26.10 73 7057 194374 90426943
Arrhythmia 55.50 26.10 37 7093 42295 90579022
Systemic infection 52.05 26.10 18 7112 4757 90616560
Gastrointestinal haemorrhage 50.95 26.10 48 7082 90200 90531117
Syncope 48.66 26.10 56 7074 132607 90488710
Shock haemorrhagic 44.71 26.10 21 7109 12224 90609093
Painful respiration 43.33 26.10 14 7116 3004 90618313
Upper gastrointestinal haemorrhage 42.52 26.10 25 7105 22951 90598366
Cerebral haemorrhage 42.44 26.10 29 7101 34493 90586824
Foetal chromosome abnormality 41.68 26.10 6 7124 21 90621296
Hypertensive crisis 40.04 26.10 22 7108 17762 90603555
International normalised ratio abnormal 40.00 26.10 14 7116 3831 90617486
Dyspnoea 38.77 26.10 154 6976 880801 89740516
Eosinophilic granulomatosis with polyangiitis 37.40 26.10 12 7118 2518 90618799
Coagulopathy 37.05 26.10 23 7107 23266 90598051
Epistaxis 36.48 26.10 39 7091 85086 90536231
Skin haemorrhage 36.27 26.10 22 7108 21358 90599959
Circulatory collapse 35.64 26.10 23 7107 24881 90596436
Faecaloma 35.36 26.10 17 7113 10414 90610903
Muscle rupture 34.85 26.10 12 7118 3129 90618188
Renal impairment 34.51 26.10 42 7088 105379 90515938
Vitamin K deficiency 34.49 26.10 8 7122 497 90620820
Pulmonary vein occlusion 34.08 26.10 6 7124 90 90621227
Urogenital haemorrhage 33.69 26.10 7 7123 260 90621057
Hypotension 33.58 26.10 77 7053 325320 90295997
Lactic acidosis 30.71 26.10 28 7102 50435 90570882
Fracture 30.63 26.10 20 7110 22056 90599261
Vascular graft infection 30.45 26.10 5 7125 48 90621269
Renal failure 30.25 26.10 44 7086 130963 90490354
International normalised ratio decreased 30.08 26.10 12 7118 4712 90616605
Dysmorphism 29.23 26.10 10 7120 2558 90618759
Lower gastrointestinal haemorrhage 28.66 26.10 14 7116 8878 90612439
Accidental overdose 28.40 26.10 21 7109 28252 90593065
Disturbance in attention 28.39 26.10 26 7104 47083 90574234
Angina pectoris 28.38 26.10 24 7106 39136 90582181
Dizziness 28.27 26.10 106 7024 589178 90032139
Tachycardia 28.10 26.10 47 7083 157626 90463691
Hygroma colli 28.02 26.10 4 7126 13 90621304
Labelled drug-food interaction medication error 27.67 26.10 6 7124 274 90621043
Blood loss anaemia 26.92 26.10 14 7116 10126 90611191
Overdose 26.76 26.10 46 7084 157663 90463654
Orthostatic intolerance 26.66 26.10 8 7122 1346 90619971
Dandy-Walker syndrome 26.63 26.10 5 7125 109 90621208
Gastric ulcer perforation 26.63 26.10 8 7122 1352 90619965

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 201.35 22.17 105 9756 26007 42585467
General physical health deterioration 160.89 22.17 186 9675 151060 42460414
Product monitoring error 157.36 22.17 53 9808 4370 42607104
International normalised ratio abnormal 129.64 22.17 43 9818 3380 42608094
Contraindicated product administered 92.78 22.17 63 9798 25209 42586265
International normalised ratio increased 87.10 22.17 79 9782 48089 42563385
Rectal prolapse 85.71 22.17 21 9840 547 42610927
Intestinal haemorrhage 82.74 22.17 32 9829 3919 42607555
Renal cyst haemorrhage 81.65 22.17 21 9840 669 42610805
Haematoma 75.71 22.17 58 9803 27965 42583509
Dizziness 71.01 22.17 169 9692 249085 42362389
Abdominal wall haemorrhage 67.37 22.17 17 9844 501 42610973
Platelet dysfunction 64.62 22.17 15 9846 308 42611166
Vena cava injury 63.68 22.17 15 9846 329 42611145
Blood glucose fluctuation 61.48 22.17 27 9834 4560 42606914
SARS-CoV-2 antibody test positive 61.28 22.17 15 9846 389 42611085
Vascular anastomotic haemorrhage 59.78 22.17 14 9847 299 42611175
Oedema peripheral 59.41 22.17 110 9751 135966 42475508
Carotid arteriosclerosis 56.45 22.17 21 9840 2311 42609163
Delayed graft function 53.96 22.17 21 9840 2614 42608860
Cardiac failure 52.53 22.17 91 9770 106765 42504709
Drug ineffective 52.08 22.17 42 9819 630155 41981319
Syncope 51.96 22.17 87 9774 99319 42512155
Vascular compression 51.58 22.17 13 9848 381 42611093
Aortic dilatation 51.56 22.17 18 9843 1651 42609823
Haematochezia 50.72 22.17 65 9796 58371 42553103
Dyspnoea 50.57 22.17 219 9642 442402 42169072
Respiratory tract haemorrhage 50.56 22.17 17 9844 1392 42610082
Blood glucose abnormal 50.43 22.17 27 9834 7026 42604448
Spinal stenosis 49.99 22.17 26 9835 6380 42605094
Hyperparathyroidism secondary 49.82 22.17 18 9843 1824 42609650
Actinic keratosis 49.17 22.17 24 9837 5152 42606322
Intraductal papillary mucinous neoplasm 48.74 22.17 13 9848 478 42610996
Perineal cyst 46.92 22.17 11 9850 236 42611238
Gastrointestinal haemorrhage 46.43 22.17 82 9779 97644 42513830
Aortic arteriosclerosis 46.43 22.17 23 9838 5097 42606377
Abnormal clotting factor 46.37 22.17 9 9852 74 42611400
Mean cell volume increased 45.90 22.17 21 9840 3902 42607572
Electrolyte imbalance 45.31 22.17 35 9826 17066 42594408
Blood 25-hydroxycholecalciferol decreased 43.33 22.17 11 9850 332 42611142
Hepatosplenomegaly 42.45 22.17 21 9840 4639 42606835
Renal artery stenosis 42.31 22.17 17 9844 2300 42609174
Intervertebral disc space narrowing 41.82 22.17 14 9847 1131 42610343
Gamma-glutamyltransferase increased 41.33 22.17 44 9817 32453 42579021
Off label use 40.83 22.17 53 9808 638282 41973192
Diverticulum intestinal 40.61 22.17 21 9840 5092 42606382
Renal failure 39.23 22.17 96 9765 143630 42467844
Arrhythmia 38.41 22.17 47 9814 40270 42571204
Spinal osteoarthritis 37.56 22.17 24 9837 8662 42602812
Fall 35.53 22.17 127 9734 234393 42377081
Basal cell carcinoma 34.76 22.17 34 9827 22699 42588775
Therapeutic drug monitoring analysis not performed 33.22 22.17 10 9851 572 42610902
Restless legs syndrome 32.98 22.17 23 9838 9591 42601883
Urinary incontinence 32.37 22.17 32 9829 21636 42589838
Squamous cell carcinoma of skin 31.44 22.17 25 9836 12701 42598773
JC virus CSF test positive 30.14 22.17 7 9854 144 42611330
Swelling of eyelid 30.06 22.17 13 9848 2115 42609359
Femoral neck fracture 29.77 22.17 16 9845 4193 42607281
Febrile neutropenia 29.55 22.17 4 9857 185699 42425775
Prothrombin time abnormal 29.12 22.17 10 9851 873 42610601
Left ventricular hypertrophy 28.98 22.17 21 9840 9298 42602176
Language disorder 28.17 22.17 13 9848 2462 42609012
Bradycardia 27.57 22.17 61 9800 85423 42526051
Glycosylated haemoglobin increased 26.93 22.17 23 9838 12901 42598573
Large intestine polyp 26.83 22.17 20 9841 9245 42602229
Implant site inflammation 26.80 22.17 6 9855 104 42611370
Cognitive disorder 26.52 22.17 36 9825 34136 42577338
Dyspnoea exertional 26.31 22.17 44 9817 50104 42561370
Nocturia 26.15 22.17 22 9839 12090 42599384
Vitamin D decreased 26.02 22.17 15 9846 4500 42606974
C-reactive protein increased 25.96 22.17 50 9811 63510 42547964
Benign prostatic hyperplasia 25.87 22.17 28 9833 21024 42590450
Spontaneous haemorrhage 25.16 22.17 8 9853 549 42610925
Mean cell haemoglobin concentration 25.07 22.17 5 9856 48 42611426
Product use in unapproved indication 24.97 22.17 6 9855 184450 42427024
Anaemia 24.78 22.17 129 9732 280149 42331325
Soft tissue haemorrhage 24.38 22.17 6 9855 159 42611315
Drug interaction 24.38 22.17 124 9737 266875 42344599
Enterobacter sepsis 24.23 22.17 9 9852 986 42610488
Nail bed inflammation 23.80 22.17 6 9855 176 42611298
Linear IgA disease 23.79 22.17 11 9850 2092 42609382
Coagulation test abnormal 23.78 22.17 8 9853 656 42610818
Contusion 23.59 22.17 38 9823 41947 42569527
Labelled drug-drug interaction medication error 23.25 22.17 23 9838 15559 42595915
Circulatory collapse 23.22 22.17 28 9833 23608 42587866
Product dose omission issue 23.01 22.17 4 9857 154361 42457113
Activated partial thromboplastin time prolonged 22.85 22.17 23 9838 15880 42595594
Haemorrhage 22.75 22.17 46 9815 60517 42550957
Prothrombin level decreased 22.69 22.17 9 9852 1177 42610297

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product prescribing error 466.59 21.30 199 15583 51132 110522385
Product monitoring error 409.02 21.30 116 15666 8811 110564706
General physical health deterioration 362.60 21.30 370 15412 424925 110148592
International normalised ratio increased 193.21 21.30 132 15650 86640 110486877
Haematoma 179.76 21.30 109 15673 58367 110515150
Haematochezia 170.04 21.30 137 15645 115387 110458130
International normalised ratio abnormal 155.48 21.30 51 15731 6306 110567211
Anaemia 143.01 21.30 269 15513 546817 110026700
Drug interaction 127.01 21.30 243 15539 499940 110073577
Labelled drug-drug interaction medication error 114.90 21.30 64 15718 29238 110544279
Atrial fibrillation 102.32 21.30 144 15638 229498 110344019
Cardiac failure 97.80 21.30 127 15655 187499 110386018
Drug ineffective 97.49 21.30 48 15734 1520492 109053025
Therapeutic drug monitoring analysis not performed 97.09 21.30 27 15755 1904 110571613
Arrhythmia 97.01 21.30 80 15702 69495 110504022
Bradycardia 96.66 21.30 115 15667 155402 110418115
Syncope 96.21 21.30 131 15651 202405 110371112
Gastrointestinal haemorrhage 92.50 21.30 116 15666 165402 110408115
Renal cyst haemorrhage 89.68 21.30 21 15761 740 110572777
Dyspnoea 83.60 21.30 345 15437 1106527 109466990
Dizziness 80.34 21.30 250 15532 697943 109875574
Fall 76.85 21.30 224 15558 603258 109970259
Prothrombin time prolonged 71.23 21.30 39 15743 17222 110556295
Vena cava injury 70.54 21.30 15 15767 337 110573180
Abdominal wall haemorrhage 69.20 21.30 17 15765 736 110572781
SARS-CoV-2 antibody test positive 68.08 21.30 15 15767 400 110573117
Vascular anastomotic haemorrhage 66.52 21.30 14 15768 299 110573218
Electrolyte imbalance 65.47 21.30 49 15733 36979 110536538
Platelet dysfunction 64.74 21.30 15 15767 504 110573013
Renal failure 64.74 21.30 116 15666 226458 110347059
Rectal prolapse 64.44 21.30 21 15761 2542 110570975
Oedema peripheral 63.61 21.30 143 15639 328517 110245000
Actinic keratosis 62.99 21.30 27 15755 6986 110566531
Pallor 62.65 21.30 57 15725 56410 110517107
Carotid arteriosclerosis 60.81 21.30 21 15761 3036 110570481
Off label use 59.99 21.30 76 15706 1500109 109073408
Circulatory collapse 59.00 21.30 49 15733 42944 110530573
Arthralgia 55.51 21.30 21 15761 779611 109793906
Intestinal haemorrhage 55.38 21.30 25 15757 7316 110566201
Acute kidney injury 54.97 21.30 207 15575 635223 109938294
Aortic dilatation 54.84 21.30 18 15764 2228 110571289
Aortic arteriosclerosis 54.42 21.30 28 15754 10910 110562607
Haematuria 54.21 21.30 63 15719 82942 110490575
Delayed graft function 54.02 21.30 21 15761 4236 110569281
Respiratory tract haemorrhage 52.66 21.30 17 15765 1997 110571520
Perineal cyst 52.35 21.30 11 15771 233 110573284
Dehydration 51.16 21.30 119 15663 279392 110294125
Electrocardiogram abnormal 50.18 21.30 32 15750 18677 110554840
Gamma-glutamyltransferase increased 49.49 21.30 52 15730 61257 110512260
Vascular compression 48.99 21.30 13 15769 768 110572749
Coagulopathy 48.74 21.30 43 15739 40868 110532649
Hyperparathyroidism secondary 48.04 21.30 18 15764 3286 110570231
Intraductal papillary mucinous neoplasm 47.76 21.30 13 15769 846 110572671
Spinal stenosis 47.19 21.30 31 15751 19025 110554492
Muscle rupture 46.18 21.30 19 15763 4441 110569076
Blood 25-hydroxycholecalciferol decreased 45.03 21.30 11 15771 465 110573052
Hepatosplenomegaly 44.20 21.30 21 15761 6898 110566619
Coagulation test abnormal 43.98 21.30 14 15768 1572 110571945
Orthostatic intolerance 43.72 21.30 15 15767 2126 110571391
Drug intolerance 43.41 21.30 4 15778 406508 110167009
Spontaneous haemorrhage 43.38 21.30 13 15769 1195 110572322
Renal artery stenosis 42.44 21.30 17 15765 3709 110569808
Presyncope 42.22 21.30 43 15739 48844 110524673
Overdose 42.18 21.30 99 15683 233695 110339822
Disorientation 41.80 21.30 51 15731 70620 110502897
Intervertebral disc space narrowing 41.52 21.30 14 15768 1882 110571635
Blood loss anaemia 41.44 21.30 28 15754 17997 110555520
Mean cell volume increased 40.51 21.30 21 15761 8309 110565208
Product use in unapproved indication 39.33 21.30 8 15774 447369 110126148
Benign prostatic hyperplasia 38.79 21.30 27 15755 18207 110555310
Abnormal clotting factor 37.61 21.30 8 15774 180 110573337
Diverticulum intestinal 36.38 21.30 22 15760 11697 110561820
Blood glucose fluctuation 36.27 21.30 19 15763 7679 110565838
Squamous cell carcinoma of skin 35.49 21.30 25 15757 17178 110556339
Hypotension 35.22 21.30 158 15624 523691 110049826
Shock haemorrhagic 35.21 21.30 30 15752 27217 110546300
Language disorder 35.21 21.30 15 15767 3823 110569694
Abdominal discomfort 34.70 21.30 7 15775 393851 110179666
Blood glucose abnormal 34.41 21.30 22 15760 12894 110560623
Right ventricular failure 34.40 21.30 29 15753 25925 110547592
Urticaria 34.40 21.30 3 15779 318854 110254663
Upper gastrointestinal haemorrhage 34.35 21.30 39 15743 50057 110523460
Spinal osteoarthritis 34.10 21.30 26 15756 20157 110553360
Activated partial thromboplastin time prolonged 33.86 21.30 27 15755 22341 110551176
Tachycardia 32.52 21.30 88 15694 226557 110346960
Epistaxis 32.51 21.30 63 15719 130309 110443208
Basal cell carcinoma 32.33 21.30 36 15746 45234 110528283
Restlessness 32.30 21.30 40 15742 56219 110517298
Painful respiration 32.25 21.30 14 15768 3733 110569784
Foetal chromosome abnormality 32.10 21.30 5 15777 16 110573501
Hypersensitivity 32.01 21.30 9 15773 403989 110169528
Melaena 31.87 21.30 44 15738 68713 110504804
Hypertensive crisis 31.83 21.30 27 15755 24345 110549172
Left ventricular hypertrophy 31.47 21.30 21 15761 13223 110560294
Joint swelling 31.35 21.30 12 15770 442833 110130684
Stevens-Johnson syndrome 31.29 21.30 36 15746 46865 110526652
JC virus CSF test positive 31.17 21.30 7 15775 204 110573313
Renal impairment 30.97 21.30 77 15705 188368 110385149
Anxiety 30.67 21.30 6 15776 345072 110228445
Prothrombin time abnormal 30.20 21.30 10 15772 1272 110572245
Blood potassium increased 30.09 21.30 30 15752 33219 110540298
Product dose omission issue 29.89 21.30 5 15777 321777 110251740
Chronic kidney disease 29.78 21.30 45 15737 76246 110497271
Fracture 29.42 21.30 26 15756 24762 110548755
Systemic infection 29.36 21.30 18 15764 9801 110563716
Cerebral haemorrhage 29.26 21.30 41 15741 64927 110508590
Febrile neutropenia 29.25 21.30 5 15777 316762 110256755
Sinusitis 28.95 21.30 4 15778 296684 110276833
Pulmonary vein occlusion 28.42 21.30 6 15776 130 110573387
Haemorrhage 28.38 21.30 53 15729 106639 110466878
Toxic epidermal necrolysis 27.35 21.30 37 15745 56690 110516827
Mean cell haemoglobin concentration 27.29 21.30 5 15777 50 110573467
Lactic acidosis 27.09 21.30 48 15734 92763 110480754
Prothrombin level decreased 26.82 21.30 10 15772 1800 110571717
Nocturia 26.77 21.30 21 15761 16969 110556548
Large intestine polyp 26.71 21.30 20 15762 15097 110558420
Treatment failure 26.44 21.30 4 15778 277230 110296287
Prothrombin time shortened 26.18 21.30 12 15770 3634 110569883
Labelled drug-food interaction medication error 25.83 21.30 6 15776 204 110573313
Restless legs syndrome 25.64 21.30 24 15758 24602 110548915
Arthropathy 25.55 21.30 5 15777 287517 110286000
Stomatitis 25.54 21.30 4 15778 270238 110303279
Urinary incontinence 25.44 21.30 33 15749 48554 110524963
Vitamin K deficiency 25.00 21.30 8 15774 913 110572604
Rash 24.73 21.30 50 15732 820914 109752603
Glycosylated haemoglobin increased 24.55 21.30 23 15759 23596 110549921
International normalised ratio decreased 24.38 21.30 15 15767 8221 110565296
Completed suicide 24.29 21.30 3 15779 242378 110331139
Muscle haemorrhage 24.21 21.30 14 15768 6855 110566662
Implant site inflammation 23.92 21.30 6 15776 283 110573234
Gastric haemorrhage 23.64 21.30 19 15763 15896 110557621
Maternal exposure during pregnancy 23.58 21.30 4 15778 254879 110318638
Systemic lupus erythematosus 23.51 21.30 4 15778 254334 110319183
Disturbance in attention 23.39 21.30 36 15746 61959 110511558
Complications of transplanted kidney 23.17 21.30 14 15768 7428 110566089
Post procedural haematuria 23.08 21.30 6 15776 327 110573190
Femoral neck fracture 23.04 21.30 17 15765 12550 110560967
Malaise 22.81 21.30 38 15744 671781 109901736
Cardiorenal syndrome 22.71 21.30 9 15773 1909 110571608
Intentional product use issue 22.69 21.30 4 15778 247902 110325615
Pain 22.58 21.30 66 15716 954889 109618628
Faecaloma 22.57 21.30 18 15764 14890 110558627
Dyspnoea exertional 22.03 21.30 47 15735 104013 110469504
Swelling of eyelid 21.97 21.30 13 15769 6640 110566877
Skin haemorrhage 21.73 21.30 22 15760 24805 110548712
Vertigo 21.67 21.30 42 15740 86828 110486689
Nasopharyngitis 21.50 21.30 15 15767 394346 110179171
Cardiovascular disorder 21.45 21.30 21 15761 22739 110550778
Soft tissue haemorrhage 21.30 21.30 6 15776 443 110573074

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AA04 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Vitamin K antagonists
FDA EPC N0000175476 Vitamin K Antagonist
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
FDA MoA N0000175964 Vitamin K Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:50390 EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor

Related Drugs by ATC class:

B01AA Vitamin K antagonists 9 drugs
acenocoumarolclorindionedicoumaroldiphenadioneethyl biscoumacetatefluindionephenindionetioclomarolwarfarin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Myocardial infarction indication 22298006 DOID:5844
Thromboembolic disorder indication 371039008
Thrombosis indication 439127006
Prosthetic replacement of heart valve off-label use 307279007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.51 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Vitamin K epoxide reductase complex subunit 1 Enzyme INHIBITOR IC50 5.75 SCIENTIFIC LITERATURE CHEMBL
Pol polyprotein Enzyme Ki 6.10 CHEMBL
Vitamin K epoxide reductase complex subunit 1 Enzyme Ki 6.70 CHEMBL

External reference:

IDSource
4018525 VUID
N0000146847 NUI
D05457 KEGG_DRUG
4018525 VANDF
C0031444 UMLSCUI
CHEBI:50438 CHEBI
CHEMBL1465 ChEMBL_ID
DB00946 DRUGBANK_ID
D010644 MESH_DESCRIPTOR_UI
54680692 PUBCHEM_CID
6839 IUPHAR_LIGAND_ID
247 INN_ID
Q08SIO485D UNII
8150 RXNORM
002086 NDDF
59488002 SNOMEDCT_US
Q08SIO485D INXIGHT DRUGS

Pharmaceutical products:

None